Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin or liposomal doxorubicin or topotecan or paclitaxel
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The input 'liposomal doxorubicin or liposomal doxorubicin or topotecan or paclitaxel' refers to a non-specific query encompassing three distinct antineoplastic agents: liposomal doxorubicin, topotecan, and paclitaxel. Each of these drugs is a chemotherapy agent used in the treatment of various cancers, but they possess different chemical structures, mechanisms of action, and clinical profiles. Liposomal doxorubicin is a formulation of the anthracycline doxorubicin, encapsulated in liposomes to alter its pharmacokinetic properties and reduce cardiotoxicity. Topotecan is a topoisomerase I inhibitor, while paclitaxel is a taxane that stabilizes microtubules.
- Brand names
- DoxilLipodoxLipodox 50Lipodox50Lipodox-50CaelyxMyocetOncodoxPegardriaPeg-JoxorubDoxojasHycamtinPotactasolTaxolAbraxaneOnxolAnzataxMitotaxDutaxelPaclitaxIntaxelPacliaqualipPacliteroCytaxNanoxelBevetexAbitaxel GemepeAclipakAcoexcel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on liposomal doxorubicin or liposomal doxorubicin or topotecan or paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin or liposomal doxorubicin or topotecan or paclitaxel.